Splash Clinical and C2N to improve Alzheimer’s trial recruitment process
C2N’s test is designed for individuals aged 55 and above who exhibit signs or symptoms of mild cognitive impairment or dementia.
Medical Devices
Johnson & Johnson MedTech introduces electrosurgical generator
Enable Injections’ syringe transfer system gains CE mark approval
Alcon signs merger agreement to acquire Lensar
Pearsanta acquires patents for adductomics-based DNA damage detection
FDA grants 510(k) clearance for Huntleigh’s CTG Analysis
Newronika’s DBS device gains CE Mark approval for Parkinson’s treatment
FDA clears Vent Creativity’s software solution for knee arthroplasty procedures
